Skip to main content

Idiopathic Osteoporosis

Genetic variants in melatonin receptor linked to idiopathic osteoporosis


Osteoporosis is a common bone disorder characterized by low bone mass and increased fracture risk, usually affecting postmenopausal women and men over the age of 60.

Idiopathic osteoporosis (IOP) is a rare form of early-onset osteoporosis that is seen in individuals under 50 years of age without any known metabolic or hormonal causes. Family histories of osteoporosis and childhood fractures suggest a genetic basis for IOP, though many cases remain unexplained despite previous genetic studies.

In the study, "Melatonin receptor 1A variants as genetic cause of idiopathic osteoporosis," published in Science Translational Medicine, researchers examined melatonin receptor variants as a potential genetic cause of IOP. They focused on the variant rs374152717, found in an Ashkenazi family with IOP, and rs28383653, identified in unrelated IOP patients.

Whole-exome sequencing was conducted on an Ashkenazi family affected by IOP, as well as a cohort of 75 unrelated women with IOP. The rs374152717 variant was present in individuals with IOP in the Ashkenazi family but absent in unaffected relatives.

This mutation was more frequent in the Ashkenazi population (0.9%) than in the general population (0.0004%). In the unrelated cohort, the rs28383653 variant was found in 4% of IOP patients.

A mouse model was used to investigate the functional consequences of the rs374152717 mutation. Mice carrying the human mutation exhibited low bone mass, a hallmark of osteoporosis, which the scientists traced to defects in osteoblast function.

Osteoblasts are the cells responsible for bone formation. These cells were found to experience senescence, an accelerated aging or premature shutting down of cellular activity due to the mutation. This senescent state impaired their ability to differentiate and build bone properly.

Further analysis in human cells confirmed that the rs374152717 mutation disrupted melatonin signaling, leading to the production of a dysfunctional MTNR1A protein and subsequent bone degeneration.

Melatonin signaling normally promotes bone formation and inhibits bone resorption, but the mutations caused abnormal regulation of cyclic AMP, calcium signaling, and mitogen-activated protein kinase pathways, which triggered osteoblast senescence and bone loss.

The findings point to a possible source for the mysterious idiopathic osteoporosis condition and suggest that genetic screening for MTNR1A variants could be a primary investigation for individuals with unexplained bone loss.



Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more